

share
Methenamine Hippurate CAS NO 5714-73-8
Unit Price:
CAS No.:5714-73-8
Grade:Pharmacy Grade
Content:99.9%
Brand:Customizable
Packaging:Customizable
Description
Methenamine Hippurate is a white to off-white crystalline powder, recognized for its role as a urinary tract antiseptic. This compound is valued for its ability to hydrolyze in acidic urine to release formaldehyde, providing a broad-spectrum antibacterial effect. It is primarily required by pharmaceutical manufacturers for the formulation of prescription and over-the-counter medications targeting uncomplicated urinary tract infections.
Application
- Pharmaceutical API: Primary active pharmaceutical ingredient (API) in prescription and OTC medications for the prophylaxis and treatment of uncomplicated lower urinary tract infections (UTIs).
- Veterinary Medicine: Used in veterinary pharmaceutical formulations for the treatment of bacterial infections in animals, particularly in companion animals and livestock.
- Clinical Research: Serves as a reference standard and key intermediate in pharmacological and microbiological research studies.
- Finished Dosage Forms: Incorporated into various solid oral dosage forms, including tablets and capsules, requiring precise and consistent API quality.
Basic Information
| Product Name | Methenamine Hippurate |
| CAS No. | 5714-73-8 |
| Molecular Formula | C9H15N4O3 |
| Molecular Weight | 227.24 g/mol |
| Synonyms | Hexamine Hippurate; Methenamine 2-Hydroxy-3,3-dimethylbutanedioate; Hippuric Acid Methenamine Salt; 1,3,5,7-Tetraazatricyclo[3.3.1.13,7]decane Hippurate; Hexamethylenetetramine Hippurate; Urotropin Hippurate; Methenamine Mono(hippurate); HIPREX (a common trade name) |
| EINECS | 227-206-5 |
Quality Control
Our Methenamine Hippurate is manufactured and tested to meet stringent pharmacopeial standards, including USP and EP monographs. Every batch undergoes comprehensive analytical testing to ensure identity, purity, strength, and composition. A detailed Certificate of Analysis (COA) is provided with each shipment, confirming compliance with agreed specifications.
Storage
Preserve in a tightly closed container, protected from light. Store in a cool, dry, well-ventilated area at controlled room temperature (15-25°C). Keep away from incompatible materials such as strong acids and strong oxidizing agents.
Specification
| Item | Specification |
|---|---|
| Appearance | White or almost white crystalline powder |
| Identification (IR) | Conforms |
| Identification (HPLC) | Conforms |
| Assay (HPLC) | 98.0% - 102.0% (on dried basis) |
| Loss on Drying | ≤ 0.5% |
| Residue on Ignition | ≤ 0.1% |
| Heavy Metals | ≤ 20 ppm |
| Related Substances (HPLC) | Individual impurity ≤ 0.5%; Total impurities ≤ 1.0% |
| Microbial Enumeration | Meets USP/EP requirements |
Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.
Hot Related Products


Sulfamethazine CAS NO 57-68-1


Halazone CAS NO 80-13-7


1,3-Dichloro-1,3,5-Triazine-2,4,6(1H,3H,5H)-Trione Sodium Salt Dihydrate CAS NO 51580-86-0


Thymol Iodide CAS NO 552-22-7


Posaconazole CAS NO 171228-49-2


Clotrimazole CAS NO 23593-75-1


Chlorhexidine Digluconate CAS NO 18472-51-0


Dioxidine CAS NO 17311-31-8


Gemifioxacin Mesylate CAS NO 210353-53-0


Tolnaftate CAS NO 2398-96-1


Miconazole Nitrate CAS NO 22832-87-7


Miconazole CAS NO 22916-47-8


Sodium 4-Aminosalicylate CAS NO 133-10-8


Vt-1161 CAS NO 1340593-59-0


Miramistin CAS NO 126338-77-0


Gardiquimod CAS NO 1020412-43-4


Sulfamerazine CAS NO 127-79-7


Furazidine CAS NO 1672-88-4


Isoconazole Nitrate CAS NO 24168-96-5


Moroxydine Hydrochloride CAS NO 3160-91-6
Why choose US
Trusted Manufacturer
With our own production facilities, we ensure consistent quality, reliable supply, and full traceability.
Rigorous Quality Assurance
Each batch undergoes strict QC, accompanied by COA, MSDS, and full compliance with international standards.
Advanced R&D Expertise
Our in-house lab drives process innovation, new product development, and tailored synthesis solutions.






